Home » Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market By Drug Type (Eluxadoline, Alosetron, Rifaximin, Loperamide, Diphenoxylate + Atropine, Dicyclomine and Hyoscyamine, Pipeline Drug Analysis: Ibodutant, Ramosetron), Prescription (Prescribed and OTC Drugs, Prescribed Branded and Prescribed Generic Drugs) – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2022 – 2028

Price: $4999

Published: | Report ID: 11189 | Report Format : PDF

The worldwide incidence of Diarrhea-Dominant Irritable Bowel Syndrome (IBS-D) is experiencing significant growth. Despite affecting millions every year, effectively diagnosing it remains challenging due to its intricate pathophysiology and unidentified risk factors connected with this ailment.

Irritable Bowel Syndrome characterized by Diarrhea (IBS-D) falls under the broader category of Irritable Bowel Syndrome (IBS), a prevalent gastrointestinal issue. IBS-D specifically denotes instances of IBS where diarrhea is the primary symptom.

IBS-D Classification IBS-D is segmented into three categories based on predominant symptoms: Diarrhea-Focused IBS (IBS-D) Constipation-Centric IBS (IBS-C) Mixed IBS (IBS-M) Market Synopsis This document explores the medicinal market aimed at treating IBS-D. Although in its infancy, the worldwide IBS-D pharmaceutical market is showing potential, especially with the launch of proprietary medicines. This has initiated further research, evolution, and the introduction of possible treatment alternatives and new market contributors. The evaluation covers diverse drug varieties, prescription segments, and global distribution.

Market Drivers:

The drug market addressing Irritable Bowel Syndrome with Diarrhea (IBS-D) is accelerated by multiple substantial factors. Foremost among these is the escalating incidence of IBS-D globally, prompting a surge in the demand for effective remedies. The growing awareness and comprehension of gastrointestinal ailments among both laypeople and healthcare experts have amplified the demand for specialized treatments. Continuous advancements in pharmaceutical R&D have led to the creation of innovative, more potent drugs, further propelling the market. Enhanced diagnostic methods, promoting swifter and more precise IBS-D diagnoses, and the move towards personalized healthcare specific to individual patient needs also play a pivotal role in the market’s growth.

Modern living patterns, marked by changes in diet and elevated stress levels, might intensify IBS symptoms, thus expanding the demographic needing treatments. Patient advocacy groups and supportive communities are pivotal in promoting disease awareness, underscoring early detection, and highlighting available treatment modalities. As emerging nations enhance their healthcare frameworks, treatment accessibility grows, augmenting demand. Moreover, supportive reimbursement policies in many advanced countries reduce direct costs for patients, fostering the adoption of IBS-D medications. Finally, as the profitability landscape of the IBS-D pharmaceutical market becomes evident, there’s a discernible increase in investment by drug companies in R&D and promotion of these medicines.

Key participants in the Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) drug market include: Astellas Pharmaceuticals Actavis Pfizer GlaxoSmithKline Salix Pharmaceuticals AstraZeneca Ironwood Pharmaceuticals Allergan Takeda Pharmaceutical Sebela Pharmaceuticals Synergy Pharmaceuticals Synthetic Biologics Bausch Health Drug Varieties The market research delves into the examination of the subsequent drugs for IBS-D management: Eluxadoline Rifaximin Alosetron Loperamide Diphenoxylate & Atropine Dicyclomine & Hyoscyamine The analysis provides market size, predictions, and Compound Annual Growth Rates (CAGRs) for these medicines from 2022 to 2028, utilizing 2021 as the reference year.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Prescription Categorization

The global IBS-D pharmaceutical market is divided into prescription and over-the-counter (OTC) medications. Further categorization within the prescription group consists of branded and generic medicines. Market size and CAGRs for these divisions are provided for the intervals 2020-2028 and 2022-2028, respectively.

Geographical Breakdown

The worldwide IBS-D medication market is split into the subsequent regions, each further dissected at the main country-level markets: North America (U.S. and Canada) Europe (U.K., Germany, and the rest of Europe) Asia Pacific (Japan, China, and the rest of Asia Pacific) Rest of the World (Middle East and North Africa, Latin America)

Qualitative Evaluation

The analysis delves into qualitative dimensions, such as motivators, obstacles, opportunities, attractive investment propositions, and competitive assessment through fractal map analysis. It wraps up by profiling dominant market entities involved in the production of IBS-D medicines.

Historical and Contemporary Developments

In the past, IBS-D sufferers had restricted medicinal choices. The sanctioning of Alosetron was succeeded by safety apprehensions, resulting in its removal and later reintroduction with limitations. In 2015, two drugs, eluxadoline (Viberzi) and Xifaxan (rifaximin), received approval for IBS-D management. Viberzi acts as an opioid antagonist, while Xifaxan adjusts gut flora to counteract diarrhea.

Regional Markets

North America dominates the IBS-D pharmaceutical market, attributed to factors like health consciousness and a high IBS incidence in the U.S. The Asia Pacific area showcases swift growth potential, attributed to an evolving healthcare structure and heightened chronic disease management awareness.

Prescription Patterns

Prescribed branded medications, namely eluxadoline and rifaximin, are anticipated to spearhead market expansion. Joint strategies for branded drugs in nascent markets are projected to amplify demand.

The IBS-D pharmaceutical market is evolving, characterized by promising therapeutic options and a broadening global influence. The sanctioning of groundbreaking drugs and sustained research bode well for those struggling with IBS-D.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Some notable trends in the IBS-D market:

  1. Personalized Treatments: With advances in genomics and a better understanding of individual patient profiles, there’s a push towards tailored treatments for IBS-D. Personalized medicine helps in predicting which treatments will be most effective for specific patient subgroups.
  2. Microbiome Research: The gut microbiome, which consists of trillions of bacteria residing in our intestines, plays a crucial role in IBS-D. There’s growing interest in understanding the specific bacterial strains associated with IBS-D and how manipulating these populations can alleviate symptoms.
  3. Dietary Interventions: The popularity of the Low-FODMAP diet has surged. This diet limits certain types of carbohydrates which can ferment in the gut and trigger IBS symptoms. Many patients are seeking dietary solutions either as an alternative or in conjunction with pharmaceutical treatments.
  4. Natural and Holistic Approaches: Alongside traditional medications, there’s increasing interest in natural remedies, including herbal supplements, probiotics, and even certain forms of physical therapy to alleviate symptoms.
  5. Mental Health Integration: The recognition of the brain-gut axis, which emphasizes the connection between mental health and gastrointestinal health, is influencing treatments. Psychological therapies, like cognitive-behavioral therapy (CBT) and mindfulness, are increasingly being recommended as part of a comprehensive IBS-D treatment strategy.
  6. Telemedicine: Given the challenges and changes induced by the COVID-19 pandemic, telemedicine consultations for IBS-D patients have become more common, allowing for consistent care even when in-person visits are challenging.
  7. Drug Development and Approvals: New drugs and therapies are in various stages of research and development, with pharmaceutical companies investing in finding more effective treatments with fewer side effects.
  8. Increased Awareness and Advocacy: With better advocacy and increased patient voice, there’s more awareness of IBS-D as a legitimate medical condition. This has led to better patient-doctor communication and more resources for patients to understand and manage their condition.
  9. Global Markets: As awareness and diagnosis rates rise, there’s an expanding market for IBS-D treatments in previously underserved regions, especially in parts of Asia and Africa.
  10. Regulatory Guidelines and Clinical Pathways: Health authorities, like the FDA in the US, are continually updating guidelines for the approval of IBS-D drugs. This ensures safety and efficacy and provides a clearer path for companies developing new treatments.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global IBS-D Drugs Market Portaiture
2.2 IBS-D Drugs Market, by Drug Type, 2021 Vs. 2028
2.3 IBS-D Drugs Market, by Prescription Type, 2021 (USD Mn)
2.4 IBS-D Drugs Market Share, by Geography, 2021 (Value %)

Chapter 3 IBS-D Drugs Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.1.1 Potential Patient Population
3.1.2 Prevalent Treatment Options for IBS-D
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Perpetual growth in IBS prevalence
3.2.2 Challenges
3.2.2.1 Low diagnosis rate and insufficient effect of drugs
3.2.3 Opportunities
3.2.3.1 Strong product pipeline
3.3 Attractive Investment Proposition
3.4 Competitive Analysis
3.4.1 Fractal Map Investigation

Chapter 4 Global IBS-D Drugs Market Analysis, by Drugs
4.1 Preface
4.2 Eluxadoline
4.3 Alosetron
4.4 Rifaximin
4.5 Loperamide
4.6 Diphenoxylate + Atropine
4.7 Dicyclomine and Hyoscyamine
4.8 Pipeline Drug Analysis: Ibodutant
4.9 Pipeline Drug Analysis: Ramosetron

Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type
5.1 Prescribed and OTC Drugs
5.2 Prescribed Branded and Prescribed Generic Drugs

Chapter 6 Global IBS-D Drugs Market Analysis, By Geography
6.1 Preface
6.2 North America
6.2.1 United States
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 Rest of Asia Pacific
6.5 Rest of the World (RoW)

Chapter 7 Company Profiles
7.1 Astellas Pharmaceuticals
7.1.1 Overview
7.1.2 Astellas Pharmaceuticals Product Portfolio
7.1.3 SCOT Analysis
7.2 Actavis
7.2.1 Overview
7.2.2 Actavis product portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Pfizer
7.3.1 Overview
7.3.2 Pfizer Product Portfolio
7.3.3 SCOT Analysis
7.4 GlaxoSmithKline
7.4.1 Overview
7.4.2 GlaxoSmithKline Product Portfolio
7.4.3 SCOT Analysis
7.5 Salix Pharmaceuticals Ltd
7.5.1 Overview
7.5.2 Salix Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 AstraZenenca
7.6.1 Overview
7.6.2 Astrazeneca Product Portfolio
7.6.3 SCOT Analysis

List of Figures

FIG. 1 IBS-D Drugs Market, by Drugs, 2021 Vs. 2028
FIG. 2 IBS-D Drugs Market, by Prescription Type, 2021 (USD Mn)
FIG. 3 IBS-D Drugs Market Share, by Geography, 2021 (Value %)
FIG. 4 IBS Physician Preference Insights
FIG. 5 Worldwide Prevalence of IBS Across Various Geographies
FIG. 6 Attractive Investment Proposition, IBS-D Drugs Market, 2021
FIG. 7 Fractal Map Investigation, Global IBS-D Drugs Market, by Key Players
FIG. 8 Global Eluxadoline (Viberzi) Market Revenue, 2020 – 2028 (USD Mn)
FIG. 9 Global Alosetron (Lotronex) Market Revenue, 2020 – 2028 (USD Mn)
FIG. 10 Global Rifaximin (Xifaxan) Market Revenue, 2020 – 2028 (USD Mn)
FIG. 11 Global Loperamide Market Revenue, 2020 – 2028 (USD Mn)
FIG. 12 Global Diphenoxylate + Atropine Market Revenue, 2020 – 2028 (USD Mn)
FIG. 13 Global Dicyclomine and Hyoscyamine Market Revenue, 2020 – 2028 (USD Mn)
FIG. 14 Canada IBS-D Drugs Market Revenue, 2019 – 2028 (USD Mn)
FIG. 15 U.K. IBS-D Drugs Market Revenue, 2020 – 2028 (USD Mn)
FIG. 16 Germany IBS-D Drugs Market Revenue, 2020 – 2028 (USD Mn)
FIG. 17 Rest of Europe IBS-D Drugs Market Revenue, 2020 – 2028 (USD Mn)
FIG. 18 China IBS-D Drugs Market Revenue, 2020 – 2028 (USD Mn)
FIG. 19 Japan IBS-D Drugs Market Revenue, 2020 – 2028 (USD Mn)
FIG. 20 Rest of Asia Pacific IBS-D Drugs Market Revenue, 2019 – 2028 (USD Mn)

List of Tables

TABLE 1 Global IBS-D Drugs Market Revenue, by Drugs, 2019 – 2028 (USD Mn)
TABLE 2 Global IBS-D Drugs Market Revenue, by Prescription Type, 2019 – 2028 (USD Mn)
TABLE 3 Global Prescribed IBS-D Drugs Market Revenue, (Branded and Generic Drugs), 2020 – 2028 (USD Mn)
TABLE 4 Global IBS-D Drugs Market Revenue, by Geography, 2020 – 2028 (USD Mn)
TABLE 5 North America IBS-D Drugs Market Revenue, by Country, 2020 – 2028 (USD Mn)
TABLE 6 U.S. IBS-D Drugs Market Revenue, by Drugs, 2020 – 2028 (USD Mn)
TABLE 7 U.S. IBS-D Drugs Market Revenue, by Prescription Type, 2019 – 2028 (USD Mn)
TABLE 8 U.S. Prescription IBS-D Drugs Market Revenue, (Branded & Generic Drugs), 2019 – 2028 (USD Mn)
TABLE 9 Europe IBS-D Drugs Market Revenue, by Country, 2019 – 2028 (USD Mn)
TABLE 10 Asia Pacific IBS-D Drugs Market Revenue, by Country, 2020 – 2028 (USD Mn)
TABLE 11 Rest of the World IBS-D Drugs Market Revenue, by Regions, 2019 – 2028 (USD Mn)

Frequently Asked Questions

What is the size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market?

The market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is expected to reach USD $XX Mn in 2028.

What is the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CAGR?

The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market?

The report is forcasted from 2022-2028.

What is the base year considered for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market?

The base year of this report is 2018.

Who are the major players in this market?

Astellas Pharmaceuticals, Astellas Pharmaceuticals Product Portfolio, SCOT Analysis, Actavis, Actavis product portfolio, Strategic Moves, SCOT Analysis, Pfizer are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN